SLP earnings

Revenue grew 8% with increases in both software and services Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its second quarter fiscal 2026, ended February 28, 2026. Second Quarter 2026 Financial Highlights (as compared to second quarter 2025) Total revenue increased 8% to $24.3 million Software revenue increased 9% to $14.6 million, representing 60% of total revenue Services revenue increased 8% to $9.7 million, representing 40% of total revenue Gross profit was $16.1 million and gross margin was 66%, compa

Conference call to be on Thursday, April 9, 2026, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report second quarter fiscal 2026 financial results after the market close on Thursday, April 9, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 201-389-0879 (int

Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025. First Quarter 2026 Financial Highlights (as compared to first quarter 2025) Total revenue decreased 3% to $18.4 million Software revenue decreased 17% to $8.9 million, representing 48% of total revenue Services revenue increased 16% to $9.5 million, representing 52% of total revenue Gross profit was $10.9 million and gross mar

Conference call to be on Thursday, January 8, 2026, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today announced that it will report first quarter fiscal 2026 financial results after the market close on Thursday, January 8, 2026. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 201-389-0879 (in

Reaffirms fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10  Investor Day on January 21, 2026, to present new product vision and AI solutions Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a global leader in cheminformatics, biosimulation, clinical operations solutions and medical communications that accelerate biopharma innovation, today reported financial results for its fourth quarter and fiscal 2025, ended August 31, 2025. Fourth Quarter 2025 Financial Highlights (as compared to fourth quarter 2024) Total revenue decreased 6% to $17.5 million Software revenue decreased 9% to $9.0 million, representi

Provides preliminary fiscal 2026 revenue guidance of $79 to $82 million and adjusted diluted EPS guidance of $1.03 to $1.10 Fourth quarter and fiscal year 2025 results to be reported December 1, 2025 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary results for its fiscal year 2025 and issued preliminary guidance and management outlook for fiscal year 2026 as follows:     Fiscal 2025 Preliminary   Fiscal 2026 Guidance Revenue   $

Updated full-year revenue guidance of between $76 to $80 million and adjusted diluted EPS of $0.93 to $1.06 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its third quarter fiscal 2025, ended May 31, 2025. Third Quarter 2025 Financial Highlights (as compared to third quarter 2024) Total revenue increased 10% to $20.4 million Software revenue increased 6% to $12.6 million, representing 62% of total revenue Services revenue increased 17% to $7.7 millio

Updates fiscal 2025 revenue guidance range Third quarter fiscal 2025 full results to be released on July 2, 2025, with conference call at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus" or the "Company"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced preliminary revenue for its third fiscal quarter and updated its full year 2025 revenue guidance. The Company expects to report third quarter fiscal 2025 revenue in the range of between $19 million and $20 million Full year fiscal 2025 revenue is expected to range between $76 millio

Total revenue grew 23% year-over-year driven by strong growth in both software and services Maintains full-year revenue guidance of $90 to $93 million and adjusted diluted EPS of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its second quarter fiscal 2025, ended February 28, 2025. Second Quarter 2025 Financial Highlights (as compared to second quarter 2024) Total revenue increased 23% to $22.4 million Software revenue increased 16% to $13.5 million, repres

Conference call to be on Thursday, April 3, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus", "SLP"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today announced that it will report second quarter fiscal 2025 financial results after the market close on Thursday, April 3, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accesse

Total revenue up 31% year-over-year primarily driven by strong software growth Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of cheminformatics, biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its first quarter fiscal 2025, ended November 30, 2024. First Quarter 2025 Financial Highlights (compared to first quarter 2024) Total revenue increased 31% to $18.9 million Software revenue increased 41% to $10.7 million, representing 57% of total revenue Services revenue increased 19% to $8.2 million, representing 43% of total revenue Gro

Conference call to be on Tuesday, January 7, 2025, at 5 p.m. ET Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today announced that it will report first quarter fiscal 2025 financial results after the market close on Tuesday, January 7, 2025. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-4

Fiscal 2024 revenue grew 18% year-over-year to $70 million, with diluted earnings per share (EPS) of $0.49 Provides fiscal 2025 revenue guidance of $90 to $93 million (+28% to +33%) and adjusted diluted EPS guidance of $1.07 to $1.20 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications to the biopharma industry, today reported financial results for its fourth quarter and fiscal 2024, ended August 31, 2024. Fourth Quarter 2024 Financial Highlights (compared to fourth quarter 2023) Total revenue increased 19% to $18.7 million Software revenue increased 6% to $

Conference call to be on Wednesday, October 23, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report fourth quarter and fiscal 2024 financial results after the market close on Wednesday, October 23, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be access

Total revenue of $18.5 million and diluted earnings per share (EPS) of $0.15 Maintains full-year revenue guidance of $69 to $72 million and updates EPS guidance Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of biosimulation, simulation-enabled performance and intelligence solutions, and medical communications for the biopharma industry, today reported financial results for its third quarter fiscal 2024, ended May 31, 2024. Third Quarter 2024 Financial Highlights (compared to third quarter 2023) Total revenue increased 14% to $18.5 million Software revenue increased 12% to $11.9 million, representing 64% of total revenue Services revenue increase

Conference call to be on Tuesday, July 2, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the inves

Total revenue of $18.3 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024. Second Quarter 2024 Financial Highlights (compared to second quarter 2023) Total revenue increased 16% to $18.3 million Software revenue increased 11% to $11.6 million, representing 63% of total revenue Services revenue increased 27% to $6.7 m

Conference call to be on Wednesday, April 3, 2024, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on th

Total revenue of $14.5 million and diluted earnings per share (EPS) of $0.10 Maintains full-year revenue guidance of $66 to $69 million (+10-15%) and EPS guidance of $0.66 to $0.68 Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter fiscal 2024, ended November 30, 2023. First Quarter Financial Highlights Total revenue increased 21% to $14.5 million Software revenue increased 25% to $7.6 million, representing 52% of total revenue Services revenue increased 17% to $6.9 million, representing 48% of total revenue

Conference call to be on Wednesday, January 3, 2024, at 5 p.m. EST Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report first quarter fiscal 2024 financial results after the market close on Wednesday, January 3, 2024. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on

Fiscal 2023 revenue increased 11% year-over-year to $59.6 million Provides Fiscal 2024 revenue guidance of $66 - $69 million (+10-15%) and EPS guidance of $0.66 - $0.68 Simulations Plus to host its Investor Day on November 14, 2023 Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its fourth quarter and fiscal 2023, ended August 31, 2023. Fourth Quarter Financial Highlights Total revenue increased 33% to $15.6 million Software revenue increased 59% to $9.3 million, representing 60% of total revenue Services revenue increased 8% to $6

Conference call to be on Wednesday, October 25, 2023, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report fourth quarter and fiscal 2023 financial results after the market close on Wednesday, October 25, 2023. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be acce

Total revenue of $16.2 million and diluted earnings per share (EPS) of $0.20 Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS guidance of $0.63 - $0.67 Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical drug discovery and development, today reported financial results for its third quarter of fiscal 2023, ended May 31, 2023. Third Quarter Financial Highlights (Fiscal 2023 vs. Fiscal 2022) Total revenue increased 9% to $16.2 million Software revenue increased 10% to $10.6 million, representing 65% of total revenue Services revenue increased 5% to $5.6 million, representing 3

Conference call to be on Thursday, July 6, 2023, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP) ("Simulations Plus"), announced today that it will report third quarter fiscal 2023 financial results after the market close on Thursday, July 6, 2023. Management will host a conference call that same day at 5:00 p.m. Eastern Time to discuss the results. Investment professionals and all current and prospective shareholders are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 1-877-451-6152 (domestic) or 1-201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the in

Total revenue of $15.8 million; Diluted Earnings Per Share (EPS) of $0.20; Maintains full-year revenue guidance of $59.3 - $62.0 million (+10-15%) and EPS Guidance of $0.63 - $0.67 Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter of fiscal 2023, ended February 28, 2023. Second Quarter Financial Highlights (Fiscal 2023 vs. Fiscal 2022) Total revenue increased 6% to $15.8 million; Software revenue increased 7% to $10.5 million, representing 67% of total revenue; Services revenue increased 4% to $5.3 million, representing 33% of

Conference call to be on Wednesday, April 5, 2023, at 5 p.m. EDT Simulations Plus, Inc. (NASDAQ:SLP), announced today that it will report financial results for the second quarter of fiscal year 2023, the period ended February 28, 2023, after the close of the financial markets on Wednesday, April 5, 2023. The Company will host a conference call on April 5, 2023, at 5:00 p.m. Eastern Time. All interested parties are invited to join the live webcast by registering here. The conference call can also be accessed by dialing 877-451-6152 (domestic) or 201-389-0879 (international) or by clicking on this Call me™ link to request a return call. The webcast can be accessed on the Investors page of

Conference call to be on Wednesday, January 4, 2023, at 5 p.m. EST Simulations Plus, Inc. (NASDAQ:SLP) announced today that it will report financial results for the first quarter of fiscal year 2023, the period ended November 30, 2022, after the close of the financial markets on Wednesday, January 4, 2023. The Company will host a conference call on January 4, 2023, at 5 p.m. Eastern Standard Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus w

Fiscal 2022 revenue increased 16% year-over-year to $53.9 million Diluted earnings per share increased 28% year-over-year to $0.60 Provides Fiscal 2023 guidance for total revenue of $59.3 million to $62.0 million (+10% to 15%) Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its fourth quarter and full-year fiscal 2022, ended August 31, 2022. "Simulations Plus delivered a strong fourth quarter, resulting in full-year revenue growth above our guidance, which, when combined with a heavy software mix and operating leverage, led to gross margin expansion and hig

Conference call to be on Wednesday, October 26, 2022, at 5:00 PM ET Simulations Plus, Inc. (NASDAQ:SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2022, the period ended August 31, 2022, after the close of the financial markets on Wednesday, October 26, 2022. The Company will host a conference call on October 26, 2022, at 5:00 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulation

Total revenue growth of 17%; Software revenue growth of 16%; Services revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 11%; Board of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its third quarter of fiscal 2022, ended May 31, 2022. "While the growth trend in our software business continued during the third quarter, our services business showed a strong recovery with 19% growth," said Shawn O'Connor, chief executive officer of Simulations Plus. "The services backlog we built over t

Conference call to be on Wednesday, July 6, 2022, at 5:00 PM ET Simulations Plus, Inc. (NASDAQ:SLP), announced today that it will report financial results for the third quarter of fiscal year 2022, the period ended May 31, 2022, after the close of the financial markets on Wednesday, July 6, 2022. The Company will host a conference call on July 6, 2022, at 5:00 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website under Confer

Total revenue growth of 13%; Software revenue growth of 25%; Diluted Earnings Per Share (EPS) growth of 40% Board of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter of fiscal 2022, ended February 28, 2022. "We generated solid revenue growth, improved margins and strong EPS growth during the second quarter, demonstrating the health of our business and the operating leverage in our model," said Shawn O'Connor, chief executive officer of Simulations Plus. "Our software business conti

Conference Call to be on Wednesday, April 6, 2022, at 5:00 PM ET Simulations Plus, Inc. (NASDAQ:SLP), announced today that it will report financial results for the second quarter of fiscal year 2022, the period ended February 28, 2022, after the close of the financial markets on Wednesday, April 6, 2022. The Company will host a conference call on April 6, 2022, at 5:00 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website und

Total revenue growth of 16%; Software revenue growth of 19%; Diluted Earnings Per Share (EPS) growth of 25% Board of Directors announces quarterly dividend of $0.06 per share Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its first quarter of fiscal 2022, ended November 30, 2021. Shawn O'Connor, chief executive officer of Simulations Plus, said, "Our software business continued to deliver higher revenue and margins in the first quarter, supplemented by improving momentum in our services business, which returned the company to overall double-digit revenue

Conference Call to be on Thursday, January 6, 2022, at 5:00 PM ET Simulations Plus, Inc. (NASDAQ:SLP), announced today that it will report financial results for the first quarter of fiscal year 2022, the period ended November 30, 2021, after the close of the financial markets on Thursday, January 6, 2022. The Company will host a conference call on January 6, 2022, at 5:00 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website

Fiscal 2021 revenue increased 12% year-over-year to $46.5 million Software revenue increased 28% year-over-year to $27.7 million Fiscal 2022 financial outlook for total revenue of $51 million to $53 million, reflecting 10% to 15% year-over-year growth Simulations Plus, Inc. (NASDAQ:SLP), a leading provider of modeling and simulation solutions for the pharmaceutical and biotechnology industries, today reported financial results for its fourth quarter and full year 2021 fiscal year, ended August 31, 2021. "We finished the year in a better position than we anticipated following our third quarter earnings report driven by both strong GastroPlus® sales and continued momentum in ADMET Predict

Conference Call to be on Monday, October 25, 2021, at 5:00 PM ET Simulations Plus, Inc. (NASDAQ:SLP), announced today that it will report its fourth quarter and full year financial results for fiscal year 2021, ended August 31, 2021, after the close of the financial markets on Monday, October 25, 2021. The Company will host a conference call on October 25, 2021, at 5:00 p.m. Eastern Time. All interested parties are invited to join the call by registering here or by calling 1-201-389-0879. Please join five to 10 minutes before the scheduled start time. The call will be simulcast live on the Internet, and the webcast will be available on the Investors page of the Simulations Plus website un